- Home
- KEP vs EXEL Comparison
KEP vs EXEL Comparison
Compare KEP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEP
- EXEL
- Stock Information
- Founded
- KEP 1961
- EXEL 1994
- Country
- KEP South Korea
- EXEL United States
- Employees
- KEP N/A
- EXEL N/A
- Industry
- KEP Electric Utilities: Central
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KEP Utilities
- EXEL Health Care
- Exchange
- KEP Nasdaq
- EXEL Nasdaq
- Market Cap
- KEP 13.3B
- EXEL 11.3B
- IPO Year
- KEP N/A
- EXEL 2000
- Fundamental
- Price
- KEP $13.73
- EXEL $43.62
- Analyst Decision
- KEP
- EXEL Buy
- Analyst Count
- KEP 0
- EXEL 18
- Target Price
- KEP N/A
- EXEL $43.00
- AVG Volume (30 Days)
- KEP 861.9K
- EXEL 3.4M
- Earning Date
- KEP 07-11-2025
- EXEL 08-05-2025
- Dividend Yield
- KEP 0.35%
- EXEL N/A
- EPS Growth
- KEP 667.18
- EXEL 237.58
- EPS
- KEP 5.56
- EXEL 2.20
- Revenue
- KEP $64,053,841,898.00
- EXEL $2,298,922,000.00
- Revenue This Year
- KEP $5.65
- EXEL $9.37
- Revenue Next Year
- KEP $2.21
- EXEL $11.05
- P/E Ratio
- KEP $5.04
- EXEL $19.80
- Revenue Growth
- KEP 4.91
- EXEL 24.49
- 52 Week Low
- KEP $6.68
- EXEL $21.82
- 52 Week High
- KEP $14.79
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- KEP 69.45
- EXEL 55.64
- Support Level
- KEP $13.93
- EXEL $42.66
- Resistance Level
- KEP $14.79
- EXEL $44.48
- Average True Range (ATR)
- KEP 0.26
- EXEL 1.57
- MACD
- KEP 0.33
- EXEL 0.08
- Stochastic Oscillator
- KEP 80.68
- EXEL 38.59
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.